VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy

Key Points

• This study aims to evaluate the efficacy of M3-F4 lipid nanoparticles in delivering CRISPR/Cas9 for treating diabetic retinopathy.
• M3-F4 lipid nanoparticles were employed for CRISPR/Cas9 delivery.
• Inflammation was measured following VEGFA exposure and treatment with M3-F4 LNP.
• Biocompatibility of the treatment was assessed.
• M3-F4 LNP significantly reduced VEGFA-induced inflammation (p<0.05).
• Biocompatibility was maintained at excellent levels with M3-F4 LNP.